Bellevue Asset Management’s Quest Diagnostics DGX Stock Holding History

Bellevue Asset Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12K	Buy	+10	New	+$1.96K	﹤0.01%	447

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Bellevue Asset Management's DGX Position: Q2 2026 in Review

Bellevue Asset Management opened a new position in Quest Diagnostics (DGX) in Q2 2026: 10 shares worth $2.12K. The stake represents ﹤0.01% of the portfolio and ranks #447 among its holdings.

1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Bellevue Asset Management held 10 shares of Quest Diagnostics worth $2.12K as of Q2 2026.
Quest Diagnostics was a new Bellevue Asset Management position in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Bellevue Asset Management's portfolio in Q2 2026, its #447 holding.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Bellevue Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.